 John Mayer
Concepts (144)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Insulin | 20 | 2022 | 2411 | 1.770 |
Why?
| | Peptides | 14 | 2022 | 985 | 1.580 |
Why?
| | Disulfides | 9 | 2020 | 107 | 1.170 |
Why?
| | Glucagon | 4 | 2021 | 109 | 0.930 |
Why?
| | Receptor, Melanocortin, Type 4 | 4 | 2007 | 19 | 0.810 |
Why?
| | Receptor, Insulin | 7 | 2022 | 105 | 0.800 |
Why?
| | Relaxin | 2 | 2017 | 20 | 0.630 |
Why?
| | Alanine | 2 | 2016 | 152 | 0.510 |
Why?
| | beta-MSH | 2 | 2007 | 2 | 0.500 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2021 | 2534 | 0.500 |
Why?
| | Somatomedins | 1 | 2016 | 27 | 0.500 |
Why?
| | Glucagon-Like Peptide 1 | 1 | 2017 | 135 | 0.490 |
Why?
| | Hypoglycemic Agents | 4 | 2021 | 1294 | 0.490 |
Why?
| | Fluorenes | 2 | 2017 | 44 | 0.440 |
Why?
| | Hypoglycemia | 3 | 2019 | 445 | 0.410 |
Why?
| | Pyridines | 1 | 2016 | 506 | 0.390 |
Why?
| | Amino Acids | 3 | 2013 | 497 | 0.380 |
Why?
| | Piperidines | 1 | 2013 | 206 | 0.370 |
Why?
| | Structure-Activity Relationship | 9 | 2021 | 570 | 0.360 |
Why?
| | Sulfhydryl Compounds | 1 | 2013 | 189 | 0.360 |
Why?
| | Molecular Structure | 7 | 2019 | 489 | 0.350 |
Why?
| | Solid-Phase Synthesis Techniques | 3 | 2020 | 15 | 0.320 |
Why?
| | Amino Acid Sequence | 11 | 2021 | 2139 | 0.320 |
Why?
| | Drug Design | 4 | 2019 | 167 | 0.320 |
Why?
| | Peptide Fragments | 3 | 2020 | 706 | 0.270 |
Why?
| | Cysteine | 2 | 2021 | 204 | 0.250 |
Why?
| | Oligopeptides | 2 | 2020 | 271 | 0.240 |
Why?
| | Combinatorial Chemistry Techniques | 1 | 2005 | 18 | 0.240 |
Why?
| | Solubility | 4 | 2021 | 245 | 0.230 |
Why?
| | Anti-Obesity Agents | 1 | 2005 | 57 | 0.220 |
Why?
| | HEK293 Cells | 5 | 2021 | 730 | 0.220 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 3 | 2021 | 82 | 0.220 |
Why?
| | Antigens, CD | 2 | 2018 | 521 | 0.210 |
Why?
| | Animals | 17 | 2022 | 36951 | 0.180 |
Why?
| | Proglucagon | 1 | 2021 | 10 | 0.180 |
Why?
| | Blood Glucose | 7 | 2021 | 2190 | 0.180 |
Why?
| | src Homology Domains | 2 | 2016 | 41 | 0.180 |
Why?
| | Infusions, Subcutaneous | 1 | 2021 | 23 | 0.180 |
Why?
| | Insulins | 1 | 2022 | 37 | 0.180 |
Why?
| | Receptors, Glucagon | 1 | 2021 | 27 | 0.170 |
Why?
| | N-Acetylneuraminic Acid | 1 | 2020 | 12 | 0.170 |
Why?
| | Proteins | 2 | 2017 | 1009 | 0.170 |
Why?
| | Peptide Synthases | 1 | 2020 | 5 | 0.170 |
Why?
| | Cyclic AMP | 2 | 2021 | 234 | 0.160 |
Why?
| | Protein Folding | 3 | 2016 | 280 | 0.160 |
Why?
| | Drug Stability | 2 | 2016 | 167 | 0.160 |
Why?
| | Drug Administration Schedule | 1 | 2021 | 786 | 0.150 |
Why?
| | Humans | 27 | 2021 | 137782 | 0.150 |
Why?
| | Small Molecule Libraries | 1 | 2019 | 94 | 0.150 |
Why?
| | Models, Molecular | 6 | 2020 | 1570 | 0.140 |
Why?
| | Amines | 1 | 2018 | 40 | 0.140 |
Why?
| | Chemistry, Pharmaceutical | 1 | 2018 | 105 | 0.140 |
Why?
| | Chromatography, High Pressure Liquid | 2 | 2013 | 597 | 0.140 |
Why?
| | Polymers | 1 | 2021 | 490 | 0.140 |
Why?
| | Metabolic Diseases | 1 | 2018 | 108 | 0.130 |
Why?
| | Rats | 4 | 2016 | 5648 | 0.130 |
Why?
| | Prodrugs | 1 | 2016 | 52 | 0.130 |
Why?
| | Gastrointestinal Agents | 1 | 2016 | 65 | 0.120 |
Why?
| | Hydrogen Bonding | 1 | 2016 | 163 | 0.120 |
Why?
| | Proline | 1 | 2016 | 79 | 0.120 |
Why?
| | Amyloid beta-Peptides | 1 | 2017 | 220 | 0.110 |
Why?
| | Tryptophan | 1 | 2016 | 183 | 0.110 |
Why?
| | Insulin Resistance | 1 | 2022 | 1211 | 0.110 |
Why?
| | Swine | 1 | 2016 | 775 | 0.110 |
Why?
| | Sequence Analysis, Protein | 1 | 2013 | 30 | 0.110 |
Why?
| | Drug Overdose | 1 | 2018 | 347 | 0.100 |
Why?
| | Protein Precursors | 1 | 2014 | 134 | 0.100 |
Why?
| | Eating | 2 | 2005 | 380 | 0.100 |
Why?
| | Hyperglycemia | 1 | 2016 | 347 | 0.090 |
Why?
| | Drug Discovery | 1 | 2013 | 142 | 0.090 |
Why?
| | Mass Spectrometry | 2 | 2017 | 739 | 0.070 |
Why?
| | Binding Sites | 2 | 2016 | 1303 | 0.070 |
Why?
| | Protein Stability | 2 | 2019 | 176 | 0.070 |
Why?
| | Receptor, IGF Type 1 | 1 | 2007 | 65 | 0.070 |
Why?
| | Melanocyte-Stimulating Hormones | 1 | 2005 | 3 | 0.060 |
Why?
| | Radioligand Assay | 1 | 2005 | 48 | 0.060 |
Why?
| | Injections, Subcutaneous | 2 | 2021 | 157 | 0.060 |
Why?
| | Protein Conformation | 2 | 2019 | 934 | 0.060 |
Why?
| | Protein Binding | 3 | 2021 | 2224 | 0.060 |
Why?
| | Neoplasms | 1 | 2019 | 2673 | 0.050 |
Why?
| | Body Weight | 2 | 2005 | 985 | 0.050 |
Why?
| | Mice | 5 | 2022 | 17794 | 0.050 |
Why?
| | Diabetes Mellitus, Experimental | 2 | 2020 | 195 | 0.050 |
Why?
| | Mice, Inbred C57BL | 3 | 2021 | 5764 | 0.050 |
Why?
| | Molecular Sequence Data | 3 | 2015 | 2900 | 0.050 |
Why?
| | Ligands | 1 | 2005 | 664 | 0.050 |
Why?
| | Cell Line | 2 | 2007 | 2847 | 0.050 |
Why?
| | Phylogeny | 1 | 2007 | 904 | 0.050 |
Why?
| | Computer Simulation | 1 | 2007 | 982 | 0.050 |
Why?
| | Organic Chemistry Phenomena | 1 | 2021 | 3 | 0.050 |
Why?
| | Weight Gain | 1 | 2005 | 519 | 0.050 |
Why?
| | Maleimides | 1 | 2021 | 23 | 0.050 |
Why?
| | Protein Subunits | 1 | 2022 | 239 | 0.050 |
Why?
| | Insulin-Like Growth Factor I | 2 | 2014 | 319 | 0.040 |
Why?
| | Cricetinae | 1 | 2021 | 289 | 0.040 |
Why?
| | Half-Life | 1 | 2021 | 164 | 0.040 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2018 | 3717 | 0.040 |
Why?
| | Signal Transduction | 3 | 2022 | 5081 | 0.040 |
Why?
| | Amides | 1 | 2021 | 93 | 0.040 |
Why?
| | Sialic Acids | 1 | 2020 | 10 | 0.040 |
Why?
| | Therapeutic Equivalency | 1 | 2020 | 32 | 0.040 |
Why?
| | Cells, Cultured | 2 | 2021 | 4193 | 0.040 |
Why?
| | Male | 5 | 2021 | 67906 | 0.040 |
Why?
| | Protein Engineering | 1 | 2019 | 97 | 0.040 |
Why?
| | Insulin Antagonists | 1 | 2018 | 8 | 0.040 |
Why?
| | Formic Acid Esters | 1 | 2017 | 4 | 0.030 |
Why?
| | Diet | 1 | 2005 | 1279 | 0.030 |
Why?
| | Macromolecular Substances | 1 | 2018 | 229 | 0.030 |
Why?
| | Proteolysis | 1 | 2018 | 177 | 0.030 |
Why?
| | Oximes | 1 | 2017 | 24 | 0.030 |
Why?
| | Cross-Linking Reagents | 1 | 2018 | 217 | 0.030 |
Why?
| | Molecular Conformation | 1 | 2017 | 145 | 0.030 |
Why?
| | Biomimetics | 1 | 2017 | 44 | 0.030 |
Why?
| | Drug Delivery Systems | 1 | 2019 | 365 | 0.030 |
Why?
| | Protein Isoforms | 1 | 2018 | 404 | 0.030 |
Why?
| | Carbon-13 Magnetic Resonance Spectroscopy | 1 | 2016 | 3 | 0.030 |
Why?
| | C-Peptide | 1 | 2017 | 163 | 0.030 |
Why?
| | Spectroscopy, Fourier Transform Infrared | 1 | 2016 | 86 | 0.030 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2016 | 560 | 0.030 |
Why?
| | Metalloendopeptidases | 1 | 2015 | 62 | 0.030 |
Why?
| | Trypsin | 1 | 2015 | 77 | 0.030 |
Why?
| | Protein Refolding | 1 | 2014 | 2 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2019 | 1052 | 0.030 |
Why?
| | Protein Structure, Secondary | 1 | 2015 | 374 | 0.030 |
Why?
| | Proinsulin | 1 | 2014 | 54 | 0.030 |
Why?
| | Amino Acid Substitution | 1 | 2014 | 307 | 0.020 |
Why?
| | Conserved Sequence | 1 | 2013 | 239 | 0.020 |
Why?
| | Sequence Alignment | 1 | 2013 | 343 | 0.020 |
Why?
| | Oxidation-Reduction | 1 | 2016 | 1060 | 0.020 |
Why?
| | Obesity | 1 | 2005 | 2993 | 0.020 |
Why?
| | Transfection | 1 | 2014 | 945 | 0.020 |
Why?
| | Isoelectric Point | 1 | 2007 | 25 | 0.020 |
Why?
| | 3T3-L1 Cells | 1 | 2007 | 36 | 0.020 |
Why?
| | Radioimmunoassay | 1 | 2007 | 173 | 0.020 |
Why?
| | Binding, Competitive | 1 | 2007 | 202 | 0.020 |
Why?
| | Injections, Intraventricular | 1 | 2005 | 55 | 0.020 |
Why?
| | Dogs | 1 | 2007 | 413 | 0.010 |
Why?
| | Rats, Long-Evans | 1 | 2005 | 125 | 0.010 |
Why?
| | Arginine | 1 | 2007 | 271 | 0.010 |
Why?
| | Lysine | 1 | 2007 | 294 | 0.010 |
Why?
| | Body Composition | 1 | 2005 | 684 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2005 | 2057 | 0.010 |
Why?
| | Energy Metabolism | 1 | 2005 | 922 | 0.010 |
Why?
| | Female | 1 | 2007 | 73465 | 0.000 |
Why?
|
|
Mayer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|